<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L452R;D614G literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L452R;D614G</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> 2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided] (<a href="https://doi.org/10.1101/2021.08.09.21261704" class="lit_link">Wilhelm et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="transmissibility">Transmissibility</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type. <br/> [In combination with E484Q caused a somewhat less 3-fold increase] (<a href="https://doi.org/10.1101/2021.05.14.444076" class="lit_link">Tada et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The L452R mutation increased the infectivity more than two-fold in these conditions.<br/> (<a href="https://doi.org/10.1101/2021.10.04.463028" class="lit_link">Mishra et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_efficacy">Vaccine efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon.<br/>Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%). (<a href="https://doi.org/10.1101/2021.09.29.21264199" class="lit_link">Bruxvoort et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).<br/> (<a href="https://doi.org/10.1101/2021.10.04.463028" class="lit_link">Mishra et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).<br/> (<a href="https://doi.org/10.1101/2021.08.09.21261704" class="lit_link">Wilhelm et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> 1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.<br/> 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.<br/> (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
